584 related articles for article (PubMed ID: 17649639)
1. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].
Tang JH; Zhao JH; Gong JP; Qin JW; Pan LQ; Xu ZY
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):210-4. PubMed ID: 17649639
[TBL] [Abstract][Full Text] [Related]
2. The effect of menopause and hysterectomy on systemic vascular endothelial growth factor in women undergoing surgery for breast cancer.
Lowery AJ; Sweeney KJ; Molloy AP; Hennessy E; Curran C; Kerin MJ
BMC Cancer; 2008 Sep; 8():279. PubMed ID: 18826631
[TBL] [Abstract][Full Text] [Related]
3. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.
Foekens JA; Peters HA; Grebenchtchikov N; Look MP; Meijer-van Gelder ME; Geurts-Moespot A; van der Kwast TH; Sweep CG; Klijn JG
Cancer Res; 2001 Jul; 61(14):5407-14. PubMed ID: 11454684
[TBL] [Abstract][Full Text] [Related]
4. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer.
Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
Cancer Invest; 2006 Oct; 24(6):576-80. PubMed ID: 16982461
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen.
Adams J; Carder PJ; Downey S; Forbes MA; MacLennan K; Allgar V; Kaufman S; Hallam S; Bicknell R; Walker JJ; Cairnduff F; Selby PJ; Perren TJ; Lansdown M; Banks RE
Cancer Res; 2000 Jun; 60(11):2898-905. PubMed ID: 10850435
[TBL] [Abstract][Full Text] [Related]
6. [Effect of concurrent chemoradiotherapy on serum vascular endothelial growth factor in esophageal squamous cell carcinoma patients--a report of 43 cases].
Wang XS; Liu MZ; Zhang CQ; Cai L; Cui NJ
Ai Zheng; 2006 Nov; 25(11):1428-32. PubMed ID: 17094915
[TBL] [Abstract][Full Text] [Related]
7. Anti-angiogenic activity of melatonin in advanced cancer patients.
Lissoni P; Rovelli F; Malugani F; Bucovec R; Conti A; Maestroni GJ
Neuro Endocrinol Lett; 2001; 22(1):45-7. PubMed ID: 11335879
[TBL] [Abstract][Full Text] [Related]
8. Changes in the circulating plasma levels of VEGF and VEGF-D after adjuvant chemotherapy in patients with breast cancer and 1 to 3 positive lymph nodes.
Kümmel S; Eggemann H; Lüftner D; Thomas A; Jeschke S; Zerfel N; Heilmann V; Emons G; Zeiser T; Ulm K; Kobl M; Korlach S; Schmid P; Sehouli J; Elling D; Blohmer JU
Anticancer Res; 2006; 26(2C):1719-26. PubMed ID: 16617567
[TBL] [Abstract][Full Text] [Related]
9. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
[TBL] [Abstract][Full Text] [Related]
10. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy.
Shariat SF; Anwuri VA; Lamb DJ; Shah NV; Wheeler TM; Slawin KM
J Clin Oncol; 2004 May; 22(9):1655-63. PubMed ID: 15117988
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of serum vascular endothelial growth factor in Egyptian females with metastatic triple negative breast cancer.
Taha FM; Zeeneldin AA; Helal AM; Gaber AA; Sallam YA; Ramadan H; Moneer MM
Clin Biochem; 2009 Sep; 42(13-14):1420-6. PubMed ID: 19576877
[TBL] [Abstract][Full Text] [Related]
12. Serum leptin, prolactin and vascular endothelial growth factor (VEGF) levels in patients with breast cancer.
Coskun U; Günel N; Toruner FB; Sancak B; Onuk E; Bayram O; Cengiz O; Yilmaz E; Elbeg S; Ozkan S
Neoplasma; 2003; 50(1):41-6. PubMed ID: 12687277
[TBL] [Abstract][Full Text] [Related]
13. VEGF in patients with non-small cell lung cancer during combination chemotherapy of carboplatin and paclitaxel.
Shingyoji M; Ando S; Nishimura H; Nakajima T; Ishikawa A; Itakura M; Iizasa T; Kimura H
Anticancer Res; 2009 Jul; 29(7):2635-9. PubMed ID: 19596939
[TBL] [Abstract][Full Text] [Related]
14. [Relationship between serum VEGF level and VEGF, COX-2 and MVD expression in breast cancer tissues].
Li EX; Wu YY; Shi F; Wu Y; Guo JJ; Dong DF
Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):522-5. PubMed ID: 18069633
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Shiono O; Kokatu T; Kubota A; Furukawa M; Tsukuda M
Am J Otolaryngol; 2005; 26(5):308-13. PubMed ID: 16137528
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
Braybrooke JP; O'Byrne KJ; Propper DJ; Blann A; Saunders M; Dobbs N; Han C; Woodhull J; Mitchell K; Crew J; Smith K; Stephens R; Ganesan TS; Talbot DC; Harris AL
Clin Cancer Res; 2000 Dec; 6(12):4697-704. PubMed ID: 11156222
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen and aromatase inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women with breast cancer.
Holmes CE; Huang JC; Pace TR; Howard AB; Muss HB
Clin Cancer Res; 2008 May; 14(10):3070-6. PubMed ID: 18483373
[TBL] [Abstract][Full Text] [Related]
18. Serum vascular endothelial growth factor is often elevated in disseminated cancer.
Salven P; Mänpää H; Orpana A; Alitalo K; Joensuu H
Clin Cancer Res; 1997 May; 3(5):647-51. PubMed ID: 9815732
[TBL] [Abstract][Full Text] [Related]
19. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer.
Feldman AL; Tamarkin L; Paciotti GF; Simpson BW; Linehan WM; Yang JC; Fogler WE; Turner EM; Alexander HR; Libutti SK
Clin Cancer Res; 2000 Dec; 6(12):4628-34. PubMed ID: 11156212
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group.
Schips L; Dalpiaz O; Lipsky K; Langner C; Rehak P; Puerstner P; Pummer K; Zigeuner R
Eur Urol; 2007 Jan; 51(1):168-73; discussion 174. PubMed ID: 16844285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
